North American pharma growing by overseas acquisitions

Tuesday, May 31, 2011 03:24 PM

European drugmakers have more competition for nearby buyouts these days, according to a report on FiercePharma. With North America's pharma companies turning to international markets for growth, they're scouting Central Europe, Eastern Europe, Turkey and the Middle East for potential generics deals, which is likely to push prices upward, experts told Dow Jones.

Most recent Central European pharma deals went to a European drugmaker or an Indian company, according to investment bankers. Now, North American companies are making acquisitions, such as Canadian drugmaker Valeant Pharmaceuticals' buyout of Lithuania's AB Sanitas and U.S.-based Watson Pharmaceuticals' purchase of Greece's Specifar.

Dow Jones said not only were the winning bidders in these deals North American, but the entire bidding pool was dominated by North American companies. That trend hasn't gone unnoticed in the M&A community; UBS has identified 17 pharma companies in "local" emerging markets that could be acquisition targets, including Hungary's Gedeon Richter and Hikma Pharmaceuticals of Jordan.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 18

Ebola outbreak highlights need to improve biosafety, infrastructure to handle future health emergencies

More African American professional women open to participating in medical research

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs